Gillian M Keating

Summary

Affiliation: Adis International Inc
Country: USA

Publications

  1. ncbi Valsartan: in chronic heart failure
    Keri Wellington
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 2:267-74; discussion 275-6. 2002
  2. ncbi Pimecrolimus: a review of its use in atopic dermatitis
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:479-95. 2004
  3. ncbi Efalizumab
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 6:113-8; discussion 119-20. 2005
  4. ncbi Spotlight on cefditoren pivoxil in bacterial infections
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Respir Med 4:149-52. 2005
  5. ncbi Ipratropium bromide HFA
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Respir Med 4:215-20; discussion 221-2. 2005
  6. ncbi Crotalidae polyvalent immune Fab: a guide to its use in North American crotaline envenomation
    Gillian M Keating
    Adis, Auckland, New Zealand
    Clin Drug Investig 32:555-60. 2012
  7. ncbi Polyphenon E 10% ointment: in immunocompetent adults with external genital and perianal warts
    Sheridan M Hoy
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Am J Clin Dermatol 13:275-81. 2012
  8. ncbi Intravenous ibuprofen: in adults for pain and fever
    Lesley J Scott
    Adis, Auckland, New Zealand
    Drugs 72:1099-109. 2012
  9. ncbi Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia
    Gillian M Keating
    Adis, Auckland, New Zealand
    Drugs 72:1111-36. 2012
  10. ncbi Ulipristal acetate: in uterine fibroids
    Jamie D Croxtall
    Adis, Auckland, New Zealand
    Drugs 72:1075-85. 2012

Collaborators

  • James E Frampton
  • Jamie D Croxtall
  • Dean M Robinson
  • Mark Sanford
  • Juliane Weber
  • C J Dunn
  • Armando Santoro
  • Jean Pierre Zellweger
  • Lesley J Scott
  • M Asif A Siddiqui
  • Caroline M Perry
  • Greg L Plosker
  • John Waugh
  • Antona J Wagstaff
  • Keri Wellington
  • Susan J Keam
  • Paul L McCormack
  • Caroline Fenton
  • Katherine A Lyseng-Williamson
  • Dene Simpson
  • Monique P Curran
  • Marit D Moen
  • Lynne M Bang
  • Sheridan M Hoy
  • David R Goldsmith
  • Sohita Dhillon
  • Susan M Cheer
  • Karen L Goa
  • Kate McKeage
  • Blair Jarvis
  • Katherine F Croom
  • Neil A Reynolds
  • Stuart Noble
  • David P Figgitt
  • Vicki Oldfield
  • Tracy Swainston Harrison
  • Toni M Dando
  • Therese M Chapman
  • Richard B R Muijsers
  • Miriam Sharpe
  • Celeste B Burness
  • Lily P H Yang
  • Emma D Deeks
  • Karly P Garnock-Jones
  • Gregory T Warner
  • Jane K McGavin
  • Claudine M Baldwin
  • Philip I Hair
  • Daniel E Hilleman
  • Vanessa R Anderson
  • Jennifer S Dickie
  • Anna J Battershill
  • Julia A Barman Balfour
  • David Murdoch
  • Ngaire J White
  • Tim Ibbotson
  • Karen McClellan
  • Lynne Bang
  • Nila Bhana
  • Gordon Mallarkey
  • Amitabh Prakash
  • Douglas Ormrod
  • Christine R Culy
  • Deborah J Cochrane
  • E B Melian
  • L J Scott
  • S E Easthope
  • B Jarvis
  • Risto S Cvetkovic
  • Stephanie Easthope
  • Jane Easton
  • Karen Goa
  • Stephanie E Easthope
  • C M Spencer
  • K L Goa

Detail Information

Publications165 found, 100 shown here

  1. ncbi Valsartan: in chronic heart failure
    Keri Wellington
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 2:267-74; discussion 275-6. 2002
    ..The most common adverse events in the valsartan and placebo groups which led to discontinuation of treatment were dizziness, renal impairment (both of which occurred in significantly more valsartan recipients) and hypotension...
  2. ncbi Pimecrolimus: a review of its use in atopic dermatitis
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:479-95. 2004
    ..Thus, topical pimecrolimus 1% cream is an effective treatment option for the management of mild-to-moderate atopic dermatitis...
  3. ncbi Efalizumab
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 6:113-8; discussion 119-20. 2005
    ....
  4. ncbi Spotlight on cefditoren pivoxil in bacterial infections
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Respir Med 4:149-52. 2005
    ....
  5. ncbi Ipratropium bromide HFA
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Respir Med 4:215-20; discussion 221-2. 2005
    ..The most common adverse events were related to respiratory system disorders. During the 1-year study, dry mouth was reported by 1.3% and 0.7% of patients in the ipratropium bromide HFA or ipratropium bromide CFC groups...
  6. ncbi Crotalidae polyvalent immune Fab: a guide to its use in North American crotaline envenomation
    Gillian M Keating
    Adis, Auckland, New Zealand
    Clin Drug Investig 32:555-60. 2012
    ..g. coagulopathy). Intravenous crotalidae polyvalent immune Fab is generally well tolerated, with acute hypersensitivity reactions being the most commonly occurring adverse event...
  7. ncbi Polyphenon E 10% ointment: in immunocompetent adults with external genital and perianal warts
    Sheridan M Hoy
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Am J Clin Dermatol 13:275-81. 2012
    ..According to pooled data from the two clinical studies, the majority of adverse events associated with polyphenon E 10% ointment involved application site and local skin reactions at the treatment site...
  8. ncbi Intravenous ibuprofen: in adults for pain and fever
    Lesley J Scott
    Adis, Auckland, New Zealand
    Drugs 72:1099-109. 2012
    ..Intravenous ibuprofen was generally well tolerated by hospitalized adult patients participating in these clinical trials. The most common adverse event leading to discontinuation of ibuprofen treatment was pruritus (<1% of patients)...
  9. ncbi Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia
    Gillian M Keating
    Adis, Auckland, New Zealand
    Drugs 72:1111-36. 2012
    ..g. nausea, vomiting and diarrhoea) and injection-site reactions among the most commonly occurring non-haematological adverse events. In conclusion, azacitidine is an important agent for use in the treatment of patients with MDS/AML...
  10. ncbi Ulipristal acetate: in uterine fibroids
    Jamie D Croxtall
    Adis, Auckland, New Zealand
    Drugs 72:1075-85. 2012
    ..Ulipristal acetate was generally well tolerated in women with uterine fibroids. The incidence of hot flush occurred with a significantly lower frequency for recipients of ulipristal acetate than for recipients of leuprolide acetate...
  11. ncbi Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US
    Katherine A Lyseng-Williamson
    Adis, Auckland, New Zealand
    Am J Cardiovasc Drugs 12:207-16. 2012
    ..Limited pharmacoeconomic analyses suggest that prasugrel-based therapy is an economically attractive treatment strategy relative to clopidogrel-based therapy from a US healthcare payer perspective...
  12. ncbi Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery
    Celeste B Burness
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 72:963-86. 2012
    ..In the meantime, dabigatran etexilate offers a convenient, effective and generally well tolerated treatment option for the prophylaxis of VTE in patients undergoing TKR and THR surgery...
  13. ncbi Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
    Sohita Dhillon
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 72:917-30. 2012
    ..Bevacizumab combination therapy had generally acceptable tolerability in these studies, with the nature of adverse events generally similar to that observed in previous clinical trials in patients with other solid tumours...
  14. ncbi Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria
    Gillian M Keating
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 72:937-61. 2012
    ..In conclusion, dihydroartemisinin/piperaquine is a valuable option for use in the first-line treatment of uncomplicated P. falciparum malaria...
  15. ncbi Quetiapine: a review of its use in the management of bipolar depression
    Mark Sanford
    Adis, Auckland, New Zealand
    CNS Drugs 26:435-60. 2012
    ..Further head-to-head trials of quetiapine versus other drug regimens that are effective in bipolar depression would be of considerable interest...
  16. ncbi Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris
    Caroline Fenton
    Adis International Limited, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:463-78. 2004
    ..The safety of calcipotriol/betamethasone dipropionate in patients treated for up to 1 year was generally good; fewer than 5% of patients experienced adverse events possibly associated with long-term corticosteroid use...
  17. ncbi The Novolizer: a multidose dry powder inhaler
    M Asif A Siddiqui
    Adis International Inc, 770 Township Line Road, Suite 300, Yardley, PA 19067, USA
    Treat Respir Med 4:63-9. 2005
    ..Overall, the Novolizer was well accepted, with an improved compliance in 80% of patients that was attributable to the control mechanisms of the device...
  18. ncbi Spotlight on insulin glargine in type 1 and 2 diabetes mellitus
    Kate McKeage
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Treat Endocrinol 1:55-8. 2002
    ..Therefore, insulin glargine is likely to be a useful addition to the armamentarium of insulin therapy by establishing basal glycemic control with once daily administration and a reduced risk of nocturnal hypoglycemia...
  19. ncbi Spotlight on estradiol and norgestimate as hormone replacement therapy in postmenopausal women
    Monique P Curran
    Adis International Limited, Langhorne, Pennsylvania 19047, USA
    Treat Endocrinol 1:127-9. 2002
    ..In the meantime, continuous oral estradiol plus intermittent oral norgestimate can be regarded as an effective new option for HRT in postmenopausal women...
  20. ncbi Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis
    David R Goldsmith
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 6:121-36. 2005
    ....
  21. ncbi Spotlight on adapalene in acne vulgaris
    John Waugh
    Adis International Inc, Yardley, PA 19067, USA
    Am J Clin Dermatol 5:369-71. 2004
    ..These attributes can potentially promote patient compliance, an important factor in treatment success. Adapalene is, therefore, assured of a role in the first-line treatment of acne vulgaris...
  22. ncbi Poly-L-lactic acid
    Caroline M Perry
    Adis International Inc Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:361-6; discussion 367-8. 2004
    ..Poly-L-lactic acid was generally well tolerated. No serious adverse events were reported...
  23. ncbi Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD
    Susan J Keam
    Adis International Inc, Yardley, Pennsylvania, USA
    Treat Respir Med 3:247-68. 2004
    ..Similar proportions of tiotropium, salmeterol, and placebo recipients required COPD-related hospitalizations. (ABSTRACT TRUNCATED)..
  24. ncbi Extended-release metformin hydrochloride. Single-composition osmotic tablet formulation
    Antona J Wagstaff
    Adis International Inc, Yardley, Pennsylvania, USA
    Treat Endocrinol 3:327-32. 2004
    ..Like the IR formulation, metformin XT is generally well tolerated; gastro-intestinal adverse events are, however, common...
  25. ncbi 17 beta-estradiol/levonorgestrel transdermal system
    Toni M Dando
    Adis International Inc, Yardley, Pennsylvania, USA
    Treat Endocrinol 3:319-24. 2004
    ..The estradiol/levonorgestrel transdermal system was generally well tolerated. In two trials, application-site reactions were common in all treatment groups (estradiol/levonorgestrel, estradiol, and placebo)...
  26. ncbi The paclitaxel (TAXUS)-eluting stent: a review of its use in the management of de novo coronary artery lesions
    John Waugh
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 4:257-68. 2004
    ..PHARMACOECONOMIC CONSIDERATIONS: Initial deployment costs associated with the PES are likely to be offset by savings in repeat procedures, according to a cost-effectiveness analysis in the UK...
  27. ncbi Omalizumab: a review of its use in the management of allergic asthma
    Lynne M Bang
    Adis International Inc, Yardley, Pennsylvania 19607, USA
    Treat Respir Med 3:183-99. 2004
    ..Comparisons of omalizumab with other asthma therapies have yet to be conducted; however, clinical efficacy and tolerability data indicate that omalizumab is a valuable option in the treatment of allergic asthma...
  28. ncbi Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection
    Caroline Fenton
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 6:177-97. 2004
    ..The use of palivizumab in these other high-risk populations is likely to be determined as much by pharmacoeconomic considerations as by efficacy outcomes...
  29. ncbi Topical methyl aminolevulinate
    M Asif A Siddiqui
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:127-37; discussion 138-40. 2004
    ..The most frequently reported adverse events were local phototoxicity reactions, most of which were of mild to moderate intensity, resolved rapidly and were rarely treatment limiting...
  30. ncbi Rosuvastatin: a review of its use in the management of dyslipidemia
    Lesley J Scott
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 4:117-38. 2004
    ..Thus, rosuvastatin has emerged as a valuable choice for first-line treatment in the management of low- to high-risk patients requiring lipid-lowering drug therapy...
  31. ncbi Lucinactant: in neonatal respiratory distress syndrome
    Marit D Moen
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Respir Med 4:139-45; discussion 146-7. 2005
    ..Adverse events were transient and related to the administration procedure. There were no differences in the incidences of complications of prematurity between lucinactant and the other surfactants...
  32. ncbi Reteplase: a review of its use in the management of thrombotic occlusive disorders
    Dene Simpson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 6:265-85. 2006
    ....
  33. ncbi Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis
    Vicki Oldfield
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 6:189-208. 2006
    ..Thus, in accordance with current clinical guidelines, bosentan is a convenient, effective, and generally well tolerated agent for use in the first-line treatment of class III PAH or second-line treatment of class IV PAH...
  34. ncbi Rotavirus vaccine (RotaTeq)
    Gillian M Keating
    Adis International Inc, Yardley, PA 19067, USA
    Paediatr Drugs 8:197-202; discussion 203-4. 2006
    ..Rotavirus vaccine and placebo were associated with serious adverse events in <3% of infants in either group...
  35. ncbi T-SPOT.TB: an in vitro diagnostic assay measuring T-cell reaction to Mycobacterium tuberculosis-specific antigens
    Antona J Wagstaff
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Mol Diagn Ther 10:57-63; discussion 64-5. 2006
    ..Unlike the TST, the RD1 ELISPOT assay is not confounded by bacille Calmette-Guérin vaccination...
  36. ncbi Spotlight on etanercept in plaque psoriasis and psoriatic arthritis
    David R Goldsmith
    Adis International Inc, 770 Township Line Road, Suite 300, Yardley, Pennsylvania 19067, USA
    BioDrugs 19:401-3. 2005
    ....
  37. ncbi Once-monthly ibandronate
    Toni M Dando
    Adis International Inc, Yardley, Pennsylvania, USA
    Treat Endocrinol 4:381-7; discussion 389-90. 2005
    ..Significantly more women with osteoporosis preferred once-monthly ibandronate and found it more convenient than once-weekly alendronate, according to data from a 6-month, randomized, open-label, crossover study...
  38. ncbi Alendronate/colecalciferol
    Neil A Reynolds
    Adis International Inc, Yardley, Pennsylvania, USA
    Treat Endocrinol 4:371-7; discussion 379. 2005
    ..The treatment-related adverse event profile of once-weekly alendronate/colecalciferol 70 mg/2800 IU was similar to that of once-weekly alendronate in the 15-week, double-blind study in patients with osteoporosis...
  39. ncbi Darbepoetin alfa: its use in anemia associated with chronic kidney disease
    Dean M Robinson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    BioDrugs 19:327-43. 2005
    ....
  40. ncbi Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism
    Dean M Robinson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 5:335-46. 2005
    ..It thus provides a valuable alternative to UFH and low-molecular weight heparins in the treatment of acute VTE, particularly in the outpatient setting...
  41. ncbi Clofarabine: in pediatric patients with acute lymphoblastic leukemia
    Monique P Curran
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 7:259-64; discussion 265-6. 2005
    ..Capillary leak syndrome or systemic inflammatory response syndrome was reported in four patients...
  42. ncbi Anakinra: a review of its use in the management of rheumatoid arthritis
    John Waugh
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    BioDrugs 19:189-202. 2005
    ..It is subcutaneously administered and is generally well tolerated. Anakinra offers a useful addition to the range of drugs available for the treatment of RA...
  43. ncbi Risedronate once a week
    Ngaire J White
    Adis International Inc, Yardley, Pennsylvania, 19067, USA
    Treat Endocrinol 2:415-20; discussion 421. 2003
    ..The tolerability profile (including the incidence of upper gastrointestinal adverse events) of risedronate 35mg once a week in women with postmenopausal osteoporosis, was similar to that of risedronate 5mg once daily...
  44. ncbi Spotlight on paricalcitol in secondary hyperparathyroidism
    Dean M Robinson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Endocrinol 4:185-6. 2005
    ..Thus, paricalcitol is a useful option for the management of secondary hyperparathyroidism in adults and children with chronic renal failure...
  45. ncbi Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive
    Susan J Keam
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Treat Endocrinol 2:49-70. 2003
    ....
  46. ncbi Spotlight on rosiglitazone in the management of type 2 diabetes mellitus
    Antona J Wagstaff
    Adis International Inc, Langhorne, Pennsylvania, USA
    Treat Endocrinol 1:411-4. 2002
    ..Rosiglitazone significantly improves insulin sensitivity and, as such, is a welcome addition to the treatment options for patients with type 2 diabetes mellitus...
  47. ncbi Intravenous conivaptan
    Marit D Moen
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Am J Cardiovasc Drugs 8:341-8; discussion 349. 2008
    ..The most common adverse events were injection related (e.g. injection-site phlebitis), hypotension, and pyrexia...
  48. ncbi Clopidogrel: potential in the prevention of cardiovascular events in patients with acute coronary syndromes
    S E Easthope
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 1:467-74; discussion 475-6. 2001
    ..However, there was no difference between the two groups in the incidence of bleeding episodes that were considered to be life-threatening...
  49. ncbi Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels
    Miriam Sharpe
    Adis International Limited, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 2:125-32; discussion 133-4. 2002
    ..In double-blind, placebo-controlled trials in a total of 804 patients, the pooled incidences of individual adverse events were generally similar with fenofibrate and placebo...
  50. ncbi Linezolid: in infants and children with severe Gram-positive infections
    Katherine A Lyseng-Williamson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 5:419-29; discussion 430-1. 2003
    ..Linezolid is generally well tolerated. The most common drug-related adverse events in the comparator-controlled trials were diarrhea, nausea, and headache; most events were mild to moderate in severity...
  51. ncbi Oxcarbazepine: a review of its use in children with epilepsy
    Lynne Bang
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 5:557-73. 2003
    ..Nevertheless, the generally favorable tolerability profile and relatively low potential for drug interactions of oxcarbazepine make it a valuable option in the treatment of childhood epilepsy...
  52. ncbi Cilostazol: a review of its use in intermittent claudication
    Therese M Chapman
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 3:117-38. 2003
    ..Nonetheless, current data support the choice of cilostazol as a promising therapy amongst the limited options available for patients with intermittent claudication...
  53. ncbi Spotlight on topical pimecrolimus in atopic dermatitis
    Keri Wellington
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Clin Dermatol 3:435-8. 2002
    ..Topical pimecrolimus 1.0% provides a promising and well tolerated treatment option in the management of infants, children and adults with mild to moderate atopic dermatitis...
  54. ncbi Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection
    Nila Bhana
    Adis International Inc, 860 Town Center Drive, Langhorne, PA 19047, USA
    Paediatr Drugs 4:515-53. 2002
    ....
  55. ncbi Cefepime: a review of its use in the management of hospitalized patients with pneumonia
    Therese M Chapman
    Adis International Inc, Langhorne, Pennsylvania 19407, USA
    Am J Respir Med 2:75-107. 2003
    ..With prudent use in order to prevent the emergence of resistant organisms, cefepime will continue to be a suitable option for the empiric treatment of pneumonia...
  56. ncbi Spotlight on zanamivir in influenza
    Susan M Cheer
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Respir Med 1:147-52. 2002
    ..Zanamivir shows potential for prophylaxis in persons for whom vaccination is contraindicated or ineffective, in elderly or high-risk patients in long-term care facilities and in households...
  57. ncbi Spotlight on montelukast in asthma in children 2 to 14 years of age
    Richard B R Muijsers
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Respir Med 1:225-8. 2002
    ..In addition, the drug offers significant benefits when added to inhaled corticosteroids (according to secondary endpoints). Montelukast offers an effective, well tolerated and convenient treatment option for children with asthma...
  58. ncbi Lamivudine: in children and adolescents with chronic hepatitis B virus infection
    Susan J Keam
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Paediatr Drugs 4:687-94; discussion 695-6. 2002
    ..Oral lamivudine is generally well tolerated by children and adolescents with chronic hepatitis B, with a similar tolerability profile to placebo at the recommended once daily dosage of 3 mg/kg up to a maximum of 100 mg/day...
  59. ncbi Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease
    Katherine A Lyseng-Williamson
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Respir Med 1:273-82; discussion 283-4. 2002
    ..Candidiasis, hoarseness/dysphonia, throat irritation and headache occurred more frequently with salmeterol/fluticasone propionate than with placebo in patients with COPD...
  60. ncbi Atomoxetine
    Dene Simpson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 5:407-15; discussion 416-7. 2003
    ..The most common treatment-related adverse event was decreased appetite. Atomoxetine shows no abuse potential and is not a controlled substance in the US...
  61. ncbi Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction
    C J Dunn
    Adis International Inc, Langhorne, Pennsylvania, USA
    Am J Cardiovasc Drugs 1:51-66. 2001
    ....
  62. ncbi Clobetasol propionate foam, 0.05%
    E B Melian
    Adis International Inc, Langhorne, Pennsylvania, USA
    Am J Clin Dermatol 2:89-92; discussion 93. 2001
    ..Clobetasol foam 7 g/day for 2 weeks induced reversible suppression of the hypothalamic-pituitary-adrenal axis in 3 out of 13 patients (methodology of assessment not provided)...
  63. ncbi Lansoprazole: in the management of gastroesophageal reflux disease in children
    Lesley J Scott
    Adis International Inc, Langhorne, Pennsylvania 10947, USA
    Paediatr Drugs 5:57-61; discussion 62. 2003
    ..The drug is generally well tolerated in children with GERD. In the largest study, the most common treatment-related adverse events occurring during therapy were constipation and headache...
  64. ncbi Calcipotriol ointment. A review of its use in the management of psoriasis
    L J Scott
    Adis International Inc, Langhorne, Pennsylvania, USA
    Am J Clin Dermatol 2:95-120. 2001
    ..Calcipotriol ointment is valuable as a first- or second-line therapy option for the management of mild to moderate psoriasis and in combination with other antipsoriatic agents for more severe psoriasis...
  65. ncbi Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization
    Tim Ibbotson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 3:381-6. 2003
    ..Abciximab remains an important therapeutic option for the prevention of complications in patients with ischaemic heart disease...
  66. ncbi Formoterol delivered by Turbuhaler: in pediatric asthma
    Susan M Cheer
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Paediatr Drugs 5:63-8; discussion 69. 2003
    ..Formoterol delivered by Turbuhaler was well tolerated in pediatric patients, with respiratory infection being the most commonly reported adverse event...
  67. ncbi Alefacept
    James Frampton
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Clin Dermatol 4:277-86; discussion 287. 2003
    ..No opportunistic infections have been reported, nor is there evidence of an increased risk of malignancies...
  68. ncbi Formoterol: a review of its use in chronic obstructive pulmonary disease
    Susan M Cheer
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Respir Med 1:285-300. 2002
    ..Thus, inhaled formoterol may be considered as a first-line option for the management of bronchoconstriction in patients with COPD who require regular bronchodilator therapy for the management of symptoms...
  69. ncbi Losartan: in the reduction of stroke risk in patients with hypertension and left ventricular hypertrophy
    John Waugh
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 3:371-7; discussion 378-9. 2003
    ..Significantly fewer losartan than atenolol recipients discontinued treatment because of adverse events, drug-related adverse events, or serious, drug-related adverse events...
  70. ncbi Flunisolide HFA
    John Waugh
    Adis International Inc, Langhorne, Pennsylvannia 19047, USA
    Am J Respir Med 1:369-72; discussion 373. 2002
    ..Flunisolide HFA was well tolerated in all trials. A long-term study found no suppression of adrenal function and minimal systemic effects were observed both in adults and children...
  71. ncbi Memantine
    Blair Jarvis
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 20:465-76; discussion 477-8. 2003
    ..Adverse events (incidence in memantine recipients greater than in placebo recipients) occurring in patients with moderately severe to severe dementia included diarrhoea, insomnia, dizziness, headache and hallucination...
  72. ncbi Clindamycin/benzoyl peroxide gel: a review of its use in the management of acne
    Gregory T Warner
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Clin Dermatol 3:349-60. 2002
    ..It is a suitable alternative for patients who are currently using topical antibacterials either alone or in conjunction with other topical anti-acne agents or systemic antibacterials...
  73. ncbi Spotlight on ranolazine in chronic stable angina pectoris
    M Asif A Siddiqui
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Am J Cardiovasc Drugs 6:357-9. 2006
    ..Nevertheless, ranolazine ER may well prove to be a useful alternative and adjunct to conventional hemodynamic antianginal therapy in the treatment of chronic stable angina...
  74. ncbi Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions
    Dene Simpson
    Adis International Limited, Auckland, New Zealand
    Drugs 65:827-58. 2005
    ....
  75. ncbi Bosentan
    Amitabh Prakash
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 2:335-43; discussion 343. 2002
    ..Those that occurred less frequently with bosentan 125 mg twice daily than with placebo included dizziness, worsening of symptoms of pulmonary arterial hypertension, cough and dyspnea...
  76. ncbi Spotlight on reteplase in thrombotic occlusive disorders
    Dene Simpson
    Wolters Kluwer Health Adis, Auckland, New Zealand
    BioDrugs 21:65-8. 2007
    ....
  77. ncbi Adapalene: a review of its use in the treatment of acne vulgaris
    John Waugh
    Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 64:1465-78. 2004
    ..These attributes can potentially promote patient compliance, an important factor in treatment success. Adapalene is, therefore, assured of a role in the first-line treatment of acne vulgaris...
  78. ncbi Spotlight on pegfilgrastim in chemotherapy-induced neutropenia
    James E Frampton
    Adis International Inc, 770 Township Line Road, Suite 300, Yardley, Pennsylvania 19067, USA
    BioDrugs 19:405-7. 2005
    ..Pegfilgrastim should, likewise, permit simplification of G-CSF-based stem cell mobilization and transplantation procedures...
  79. ncbi Saquinavir: a review of its use in boosted regimens for treating HIV infection
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    Drugs 63:1299-324. 2003
    ..Once-daily boosted saquinavir regimens may be most suitable for HIV-infected patients with busy lifestyles and those who would benefit from directly observed therapy...
  80. ncbi Spotlight on verteporfin in subfoveal choroidal neovascularisation
    Susan J Keam
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 21:203-9. 2004
    ..Thus, verteporfin therapy provides a valuable option for the management of these patients for whom treatment options are few, and should be considered as a first-line therapy in these difficult-to-manage conditions...
  81. ncbi Voriconazole: in the treatment of invasive aspergillosis
    Richard B R Muijsers
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 62:2655-64; discussion 2665-6. 2002
    ..02 both comparisons) fewer treatment-related adverse events or serious adverse events. The incidence of visual disturbances was significantly (p < 0.001) higher with voriconazole than amphotericin B treatment...
  82. ncbi Novolizer: a multidose dry powder inhaler
    Caroline Fenton
    Adis International Limited, Auckland, New Zealand
    Drugs 63:2437-45; discussion 2447-8. 2003
    ..Most patients preferred it to previously used MDIs or DPIs. Only 4-5% found the taste feedback unacceptable. Physicians observed improved compliance over 4 weeks in 80% of patients with asthma using Novolizer...
  83. ncbi Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease
    Caroline Fenton
    Adis International Limited, Auckland, New Zealand
    Drugs 64:1975-96. 2004
    ..The DPI combining a corticosteroid and long-acting beta2-agonist provides benefits over monotherapy and may encourage patient compliance in COPD...
  84. ncbi Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease
    Gillian M Keating
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 67:2383-405. 2007
    ..Thus, salmeterol/fluticasone propionate is an important option in the treatment of patients with COPD who are appropriate candidates for combination therapy with a long-acting bronchodilator and an inhaled corticosteroid...
  85. ncbi Intravenous esomeprazole
    Gillian M Keating
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 64:875-82; discussion 883. 2004
    ..Intravenous esomeprazole was generally well tolerated in patients with erosive oesophagitis, with a tolerability profile similar to that of the oral formulation...
  86. ncbi Paricalcitol: a review of its use in the management of secondary hyperparathyroidism
    Dean M Robinson
    Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand
    Drugs 65:559-76. 2005
    ..Thus, paricalcitol is a useful option for the management of secondary hyperparathyroidism in adults and children with chronic renal failure...
  87. ncbi Cinacalcet hydrochloride
    Julia A Barman Balfour
    Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 65:271-81. 2005
    ..Cinacalcet HCl was generally well tolerated in clinical trials. Most treatment-emergent adverse events were mild to moderate in severity...
  88. ncbi Intravenous ibandronate: in the treatment of osteoporosis
    Katherine F Croom
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 66:1593-601; discussion 1602-3. 2006
    ..IV ibandronate was generally well tolerated in clinical trials. Treatment-related adverse events included musculoskeletal events and transient influenza-like symptoms, the latter mainly associated with the first dose...
  89. ncbi Cetirizine: a review of its use in allergic disorders
    Monique P Curran
    Adis International Limited, Auckland, New Zealand
    Drugs 64:523-61. 2004
    ..On the basis of its favourable efficacy and tolerability profile and rapid onset of action, cetirizine provides an important option for the treatment of a wide range of allergic disorders...
  90. ncbi Tramadol/paracetamol
    Karen McClellan
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 63:1079-86; discussion 1087-8. 2003
    ..5/325 mg provided similar efficacy to that of codeine/paracetamol 30/300 mg in patients with chronic back pain in a 4-week, randomised, double-blind trial (a maximum of 10 tablets or capsules per day of the active drug)...
  91. ncbi Entecavir: a review of its use in chronic hepatitis B
    Dean M Robinson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 66:1605-22; discussion 1623-4. 2006
    ..In addition, the tolerability profile of entecavir was generally similar to that of lamivudine. Thus, entecavir is a primary option in the treatment of chronic HBV infection in both nucleoside-naive and lamivudine-refractory patients...
  92. ncbi Oxybutynin extended-release: a review of its use in the management of overactive bladder
    M Asif A Siddiqui
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 64:885-912. 2004
    ..Hence, given its overall efficacy/tolerability profile and dosage flexibility, oxybutynin ER provides an excellent treatment option in the first-line pharmacotherapy of OAB...
  93. ncbi Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents
    Katherine F Croom
    Adis International Limited, Auckland, New Zealand
    Drugs 65:2129-35; discussion 2136-7. 2005
    ..Lansoprazole was generally well tolerated in children and adolescents, with the most common treatment-related adverse events being gastrointestinal events and headache...
  94. ncbi Esomeprazole: a review of its use in the management of acid-related disorders in the US
    Lesley J Scott
    Adis International Limited, 41 Centorian Drive, PB 65901, Mairangi Bay, Auckland 10, New Zealand
    Drugs 62:1091-118. 2002
    ..Esomeprazole was also effective in patients with symptomatic GORD. Thus, esomeprazole has emerged as an effective option for first-line therapy in the management of acid-related disorders...
  95. ncbi Tacrolimus: a further update of its use in the management of organ transplantation
    Lesley J Scott
    Adis International Limited, Auckland, New Zealand
    Drugs 63:1247-97. 2003
    ..The optimal immunosuppression regimen is ultimately dependent on balancing such factors as the efficacy of the individual drugs, their tolerability, potential for drug interactions and pharmacoeconomic issues...
  96. ncbi Esomeprazole: a review of its use in the management of acid-related disorders
    Lesley J Scott
    Adis International Limited, 41 Centorian Drive, PB 65901, Mairangi Bay, Auckland 10, New Zealand
    Drugs 62:1503-38. 2002
    ..Esomeprazole also proved beneficial in patients with symptomatic GORD without oesophagitis. Thus, esomeprazole has emerged as an option for first-line therapy in the management of acid-related disorders...
  97. ncbi Ciclesonide
    Neil A Reynolds
    Adis International Limited, Auckland, New Zealand
    Drugs 64:511-9; discussion 520-1. 2004
    ..Inhaled ciclesonide was generally well tolerated in patients with asthma. Ciclesonide did not suppress biochemical markers of adrenal function in 52-week studies. The long-term (>52 weeks) systemic effects of ciclesonide remain unknown...
  98. ncbi Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation
    Susan J Keam
    Adis International Limited, Auckland, New Zealand
    Drugs 63:2521-54. 2003
    ..Thus, verteporfin therapy provides a valuable option for the management of these patients for whom treatment options are few, and should be considered as a first-line therapy in these difficult-to-manage conditions...
  99. ncbi Donepezil: in vascular dementia
    David R Goldsmith
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 20:1127-36. 2003
    ..Donepezil was generally well tolerated in patients with VaD. Most adverse events were mild to moderate in nature, with diarrhoea and nausea being the most common...
  100. ncbi Entecavir: a review of its use in chronic hepatitis B
    Lesley J Scott
    Wolters Kluwer Health Adis, 41 Centorian Drive, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 69:1003-33. 2009
    ..Hence, entecavir therapy provides a valuable first-line option in nucleoside-naive patients with chronic HBV infection and is a useful alternative in lamivudine-refractory patients...
  101. ncbi Intramuscular paliperidone palmitate
    Sheridan M Hoy
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    CNS Drugs 24:227-44. 2010
    ..Intramuscular paliperidone palmitate 39-234 mg was generally well tolerated in adult patients with schizophrenia...